ArticleJournal of ovarian research2025
Modulation of PI3K/AKT/mTOR signaling pathway by combined stem cell and phytochemical treatment improves metabolic and reproductive outcomes in PCOS.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potential of stem cells in addressing female infertility: recent progress and prospective developments.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPCOS is characterized by ovulatory dysfunction and metabolic abnormalities, and growing evidence suggests that dysregulated autophagy in ovarian granulosa cells contributes to its pathogenesis. Mesenchymal stem cells (MSCs) and Medicine Lin (ML) therapy have been proven to improve these dysfunctions in PCOS patients, enhancing fertility and pregnancy outcomes, though their underlying mechanisms remain unclear. This study hypothesized that MSCs and ML function by regulating the autophagy-mediated PI3K/AKT/mTOR signaling pathway.
methodsA PCOS mouse model was established through high-fat, high-sugar diet and letrozole induction. MSCs and ML treatment was administered for three weeks, followed by fertility testing. Ovarian morphological changes were examined using H&E and Masson staining, autophagosomes in granulosa cells were observed via transmission electron microscopy, serum hormone levels were measured by using ELISA kits, fetal umbilical blood flow was monitored with Doppler ultrasound, cell apoptosis and LC3II expression in ovarian and placental tissues were evaluated using TUNEL and immunofluorescence, and Western blot was used to analyze expressions of PI3K, AKT, FOXO1, mTOR, S6K1, Beclin1, P62, LC3II / LC3I, and ROS.
resultsCombined MSCs and ML therapy significantly improved glucose and lipid metabolism, reduced androgen levels, and addressed key endocrine disruptions. This combined therapy reduced ovarian collagen fiber formation and excessive autophagy, activating the PI3K/AKT/mTOR pathway. Additionally, it restored ovulation function, improved follicular quality, increased fertility rates, enhanced placental function, and reduced adverse pregnancy outcomes. Histological analysis showed increased ovarian microvessel density, enlarged placental labyrinth zone area, and normalized giant trophoblast cell arrangement in the treatment group. At the molecular level, MSCs and ML significantly decreased the expression of PI3K, Beclin1, P62, LC3 II/LC3I, and ROS in ovarian tissues, while upregulating p-mTOR, p-FOXO1, p-S6K1, and p-AKT expression.
conclusionThe combination of MSCs and ML inhibits excessive autophagy in ovarian granulosa cells and placental tissues of PCOS mice by regulating the PI3K/AKT/mTOR signaling pathway, while improving mitochondrial function, thereby restoring ovarian function and enhancing pregnancy outcomes. This study elucidates the role of the “autophagy-placental function” axis in PCOS pathogenesis, providing a new theoretical foundation and potential strategy for clinical PCOS treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.